Page 43 - Fool Live News Today

Author Bio Brian Withers has been a Fool since 2004 and loves to invest in companies that are disrupting the status quo. His best investment was to get his kids into Foolish stocks at the young ages of 5 & 7. Prior to starting his contract writer role with The Fool, he spent 30 years between IBM, Dell, and Allergan helping make their operations run better. When hes not writing, you can find Brian riding his bike around the Research Triangle Area in North Carolina. Feel f...

Author Bio Fool since 2011. I write about consumer goods, the big picture, and whatever else piques my interest. Follow me on Twitter to see my latest articles, and for commentary on hot topics in retail and the broad market. Follow @tmfbowman Key Points Fine dining chains are still struggling. Theres still tension between restaurants and third-party delivery apps. Remote work boomed during the pandemic, and its had a diverse range of effects on the economy. The restaur...

WallStreetBets is trying to start another short squeeze.

As the U.S. gets back to normal life, this retail stock could be a big winner.

Author Bio Matt is a Certified Financial Planner based in South Carolina who has been writing for The Motley Fool since 2012. Matt specializes in writing about bank stocks, REITs, and personal finance, but he loves any investment at the right price. Follow him on Twitter to keep up with his latest work! Follow @TMFMathGuy Looking to repeat the success of its investment in Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) recently invested $500 million in another Brazilian fin...

Is Novavaxs COVID-19 Vaccine Superior to the mRNA Vaccines? Taylor Carmichael Moderna (NASDAQ: MRNA) and  Pfizer (NYSE: PFE) have seized an early lead in vaccine distribution in the United States. Is it too late for that underdog biotech Novavax (NASDAQ: NVAX) to win market share? Or does it actually have some advantages in the rest of the world? Motley Fool healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Taylor Carmichael talk about the similarities...

Here's what investors need to know about the prominent SPAC investor's new blank-check companies.

It's playing to this ingrained human characteristic.

Three longtime investors weigh in.

Is the new logistics company worth owning?